Sugammadex and Neostigmine in Pediatric Patients
Key facts
- Who runs it
- Marmara University
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 130 people enrolled
- Started
- 8 Nov 2022
- Ended
- 15 Apr 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- Group N; neostigmine+atropine
- GROUP S; decurarized with sugammadex.
- Record updated
- 29 May 2024
Who can take part
- Age
- 5 years to 12 years
- Sex
- Women and men
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- After the approval of the local ethics committee and written consent from the family ASA 1 5-12 years old
Who cannot take part
- history of allergy or anaphylaxis to one of the drugs used children with autism children with auditory problems family without consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
In this study, it was aimed to compare the use of sugammadex instead of neostigmine + atropine in the reversal of NMB in children undergoing lower abdominal surgery or urogenital surgery, and to compare the rates of postoperative agitation, nausea and vomiting using the FLACC scale, PAED scale and ICC parameters.After the approval of the local ethics committee and written consent from the family, patients who underwent ASA 1, 5-12 years old lower abdomen surgery or urogenital surgery in Pendik Training and Research Hospital will be included in the study.
Read full original descriptionShow less
The patients included in the study will be those who were maintained with routine 2-3% sevoflurane inhalation anesthetic and 0.2mcg/kg/min remifentanil intravenous anesthetic, and decurarized with 0.5-1 mg/kg rocuronium. No drugs other than those administered by the responsible Anesthesiologist during the operation will be administered.
The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.
0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no.
The 2 groups in the trial
- neostigmin+atropin
This will be the group of patients decurarized with neostigmine+atropine,
Treatment: Group N; neostigmine+atropine
- sugammadeks
This will be the group of patients decurarized with sugammadex.
Treatment: GROUP S; decurarized with sugammadex.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison of Sugammadex and Neostigmine in Terms of Awakening, Pain, Agitation, Nausea and Vomiting in Pediatric Patients''
- Record updated
- 29 May 2024